KR920700678A - 항-박테리아 성분물 - Google Patents

항-박테리아 성분물

Info

Publication number
KR920700678A
KR920700678A KR1019910700615A KR910700615A KR920700678A KR 920700678 A KR920700678 A KR 920700678A KR 1019910700615 A KR1019910700615 A KR 1019910700615A KR 910700615 A KR910700615 A KR 910700615A KR 920700678 A KR920700678 A KR 920700678A
Authority
KR
South Korea
Prior art keywords
milk
pneumoniae
influenza
extracted
treatment
Prior art date
Application number
KR1019910700615A
Other languages
English (en)
Inventor
안데르쎈 벤그트
아니안쎈 구스타프
린드스테트 라그나르
스반보르그 에덴 카테리나
Original Assignee
안데르쎈 벤그트
아니안쎈 구스타프
린드스테트 라그나르
스반보르그 에덴 카테리나
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안데르쎈 벤그트, 아니안쎈 구스타프, 린드스테트 라그나르, 스반보르그 에덴 카테리나 filed Critical 안데르쎈 벤그트
Publication of KR920700678A publication Critical patent/KR920700678A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/202—Casein or caseinates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음

Description

항-박테리아 성분물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 소초유가 H.인플루엔자와 S.뉴모니아에 의한 흡착을 저해하는 것을 나타낸 것이다. 제2도는 카제인 농도와 흡착 저해도 사이의 상관관계를 나타낸 것이다. 제3도는 카파-카제인 농도와 흡착도 사이의 상관관계를 나타낸 것이다.

Claims (7)

  1. S.뉴모니아와 H.인플루엔자에 의한 호흡기 감염의 치료, 예방과 진단에 이용되는 제약학적인 성분물을 제조하는데 있어서 우유에서 추출한 분자량이 5000 달톤이상인 저분자로 구성된 카제인 프렉션(fraction)의 용도.
  2. 제1항에 있어서, 카제인은 인유, 소젖과 돼지젖에서 추출한 것으로 분자량이 5000달톤이상인 것을 특징으로 하는 용도.
  3. S.뉴모니아와 H.인플루엔자에 의한 호흡기 감염의 치료, 예방과 진단에 이용되는 것으로 우유에서 추출한 분자량이 5000달톤 이상인 저분자로된 카제인 플랙션의 효과량으로 구성된 것을 특징으로 하는 제약학적 성분물.
  4. 제3항에 있어서, S. 뉴모니아에 의한 감염의 치료, 또는 예방을 위한 인유, 소젖, 돼지젖에서 추출한 카제인의 치료효과와 살균효과량으로 구성된 것을 특징으로 하는 제약학적 성분물.
  5. S.뉴모니아 또는 H.인플루엔자에 의한 호흡기 감염의 치료, 또는 예방을 위한 우유에서 추출한 5000 달톤이상의 저분자로된 카제인 플렉션이 활성양이 첨가된 것을 특징으로 하는 음식과 사료.
  6. S.뉴모니아또는 H.인플루엔자에 의한 감염의 치료 또는 예방에 있어서, 우유에서 추출한 분자량이 5000달톤이상인 카제인의 효과량과 제약학적으로 비활성 촉진제 또는 영양제와 복합하여 포유류(사람 포함)에 주입시키는 것으로 구성된 것을 특징으로 하는 치료 및 예방방법.
  7. S.뉴모니아또는 H.인플루엔자에 의해 감염된 포유류(사람포함)에서 추출한 샘플조직에 제1항 내지 2항에 따르는 성분물의 흡착도를 검사함으로써 S.뉴모니아또는 H.인플루엔자에 의한 감염을 진단하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910700615A 1989-10-30 1990-10-30 항-박테리아 성분물 KR920700678A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE8903625-5 1989-10-30
SE8903625A SE465109B (sv) 1989-10-30 1989-10-30 Antibakteriell komposition
PCT/SE1990/000702 WO1991006308A1 (en) 1989-10-30 1990-10-30 A casein fraction for therapeutic, profylactic and/or diagnostic use in infections of the respiratory tract

Publications (1)

Publication Number Publication Date
KR920700678A true KR920700678A (ko) 1992-08-10

Family

ID=20377332

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910700615A KR920700678A (ko) 1989-10-30 1990-10-30 항-박테리아 성분물

Country Status (15)

Country Link
EP (1) EP0454813B1 (ko)
JP (1) JPH04503077A (ko)
KR (1) KR920700678A (ko)
AT (1) ATE170754T1 (ko)
AU (1) AU633647B2 (ko)
CA (1) CA2044244A1 (ko)
DE (1) DE69032646T2 (ko)
DK (1) DK0454813T3 (ko)
ES (1) ES2121755T3 (ko)
FI (1) FI102516B1 (ko)
HU (1) HU212935B (ko)
NO (1) NO912391D0 (ko)
RU (1) RU2035913C1 (ko)
SE (1) SE465109B (ko)
WO (1) WO1991006308A1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643880A (en) * 1994-05-26 1997-07-01 Abbott Laboratories Product for inhibition of attachment of H. influenzae to human cells
US5707968A (en) * 1994-05-26 1998-01-13 Abbott Laboratories Inhibition of attachment of H.influenzae to human cells
US5538952A (en) * 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
JPH10500100A (ja) * 1994-05-26 1998-01-06 アボツト・ラボラトリーズ 哺乳動物細胞のｒｓウイルス感染の阻害
EP0760673A1 (en) * 1994-05-26 1997-03-12 Abbott Laboratories INHIBITION OF ATTACHMENT OF $i(H. INFLUENZAE) TO HUMAN CELLS
US5506209A (en) * 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5942254A (en) * 1995-02-27 1999-08-24 Abbott Laboratories Phosphorylated recombinant human β-casein expressed in a bacterial system
JP2000500141A (ja) * 1995-11-06 2000-01-11 アボツト・ラボラトリーズ リン酸化された組換えヒトベータ−カゼインを用いるヒト細胞に対するインフルエンザ菌の付着阻止方法
EP0859629B1 (en) * 1995-11-06 2003-08-13 Abbott Laboratories Phosphorylated recombinant human beta casein for inhibition of attachment of h. influenzae to human cells
AUPP494798A0 (en) 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
BR0215954A (pt) 2002-11-26 2005-09-13 Uc Tech Métodos de redução da possibilidade de mortalidade em um animal, de expressão virulenta em um patógeno intestinal, e da expressão de adesina / lectina pa-i em uma célula bacteriana, de inibição de expressão de adesina / lectina pa-i em um patógeno intestinal, de ativação induzida por intestino de adesina / lectina pa-i, de mudança morfológica induzida por c4-hsl de um patógeno intestinal, e de aderência de célula bacteriana em um intestino de mamìfero, de melhoria de patogênese intestinal, de prevenção de uma doença ou condição anormal, de infecção de pele e respiratória, de uma doença sexualmente transmitida, de um distúrbio de trato digestivo, de perda de capacidade lactante em um animal, e de desenvolvimento de um distúrbio epitelial mediado por micróbio em uma animal de idade de amamentação, de irrigação de pelo menos uma porção do trato urinário, e para monitoração da administração de poli (etileno-glicol) (peg) a um animal, composição farmacêutica, kits para a prevenção ou tratamento terapêutico de sepsia derivada de intestino, e para a monitoração da administração de poli (etileno-glicol), e, preservativo
KR20100061441A (ko) * 2007-07-06 2010-06-07 래크리드 인코포레이티드 기도 내 생물막을 용해시키기 위한 가수분해 및 산화효소의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1496671A (en) * 1975-03-27 1977-12-30 Grindstedvaerket As Anti-cancer-active sour milk fraction
FR2491334A1 (fr) * 1980-10-03 1982-04-09 Inst Nat Sante Rech Med Nouvelles substances biologiquement actives, leur obtention a partir de caseine humaine et compositions les contenant
FR2592769B1 (fr) * 1986-01-10 1990-10-12 Agronomique Inst Nat Rech Procede d'obtention d'une matiere enrichie en caseine beta, appareillage pour la mise en oeuvre de ce procede, et application des produits obtenus par ce procede comme aliments, complements alimentaires ou additifs en industrie alimentaire et pharmaceutique ou dans la preparation de peptides a activite physiologique
JP2631470B2 (ja) * 1987-05-15 1997-07-16 雪印乳業株式会社 感染防御剤

Also Published As

Publication number Publication date
SE465109B (sv) 1991-07-29
JPH04503077A (ja) 1992-06-04
NO912391L (no) 1991-06-19
ES2121755T3 (es) 1998-12-16
ATE170754T1 (de) 1998-09-15
EP0454813B1 (en) 1998-09-09
FI102516B (fi) 1998-12-31
SE8903625D0 (sv) 1989-10-30
AU6647090A (en) 1991-05-31
HU212935B (en) 1996-12-30
WO1991006308A1 (en) 1991-05-16
CA2044244A1 (en) 1991-05-01
NO912391D0 (no) 1991-06-19
EP0454813A1 (en) 1991-11-06
DK0454813T3 (da) 1999-02-01
DE69032646T2 (de) 1999-05-27
AU633647B2 (en) 1993-02-04
RU2035913C1 (ru) 1995-05-27
FI913154A0 (fi) 1991-06-28
SE8903625L (sv) 1991-05-01
FI102516B1 (fi) 1998-12-31
DE69032646D1 (de) 1998-10-15

Similar Documents

Publication Publication Date Title
Abele-Horn et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients
KR920700678A (ko) 항-박테리아 성분물
Reimers et al. Borrelia burgdorferi myositis: report of eight patients
DE69636228D1 (de) Therapeutische Zusammensetzungen zur Behandlung von Lawsonia intracellularis Infektionen
Blaser Editorial Response: Campylobacter fetus: Emerging Infection and Model System for Bacterial Pathogenesis at Mucosal Surfaces
US4844894A (en) Method of inhibiting the onset of septicemia and endotoxemia
BR9814615A (pt) Métodos e materiais para o tratamento e prevenção de inflamação do tecido da mucosa
Cole et al. Interactions of mycoplasmas and their products with lymphoid cells in vitro
Lauschke et al. Hematogenous osteomyelitis in infants and children in the northwestern region of Namibia. Management and two-year results.
JP2001072582A (ja) 機能性経口組成物
Ljungh et al. Aeromonas hydrophila toxins—intestinal fluid accumulation and mucosal injury in animal models
Bennett The origin of myopain: An integrated hypothesis of focal muscle changes and sleep disturbance in patients with the fibromyalgia syndrome
OCHIAI et al. Neuroimaging of a Wooden Foreign Body Retained for 5 Months in the Temporalis Muscle Following Penetrating Trauma with a Chopstick—Case Report—
Sela et al. Effect of leukocyte hydrolases on bacteria: IX. The release of lipoteichoic acid from group A streptococci and from Strep, mutans by leukocyte extracts and by lysozyme: Relation to tissue damage in inflammatory sites
JPH05310594A (ja) 抗菌剤とこの抗菌剤を用いて物品を処理する方法
Majury et al. Preliminary investigation of the mechanism of inhibition of bovine lymphocyte proliferation by Pasteurella haemolytica A1 leukotoxin
NO912942L (no) Vaksine for preventiv behandling av infeksjon av leverikte hos droevtyggere.
CA2197659A1 (en) Antibacterial composition containing multimeric alpha-lactalbumin
Altemeier Bacteriology of traumatic wounds
CN111150835A (zh) 猪β-防御素2肽段在制备预防和治疗猪链球菌感染的药物组合物中的应用
OAKLEY Section of Comparative Medicine
Ziprin et al. T-2 toxin effects on the serum amyloid P-component (SAP) response of Listeria monocytogenes-and Salmonella typhimurium-infected mice
Arslan et al. Comparative evaluation of the effects of florfenicol and tulathromycin on clinical recovery and acute phase proteins in undifferentiated natural bovine respiratory disease
US20010056061A1 (en) Synthetic, statistic thymic peptide combination and its use as a preparation with immunological and/or endocrinological effect
Ayres Atopic dermatitis—a new therapeutic regimen

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application